Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10881637 | Toxicon | 2005 | 19 Pages |
Abstract
Finally, the characterization and development of alfimeprase, a recombinant fibrinolytic enzyme derived from fibrolase, as a clinical agent is described citing the progression from the laboratory bench to its current status as having successfully completed Phase II clinical trials.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry, Genetics and Molecular Biology (General)
Authors
S. Swenson, F.S. Jr,